The case for & against
Bull & Bear analysis
Bearish
Pulse Biosciences, Inc. (NASDAQ: PLSE) is an innovative medical technology company specializing in the development of its proprietary nanosecond pulse field ablation (NSPFA) technology, transforming treatment modalities in soft tissue and cardiac ablation markets. Positioned within the rapidly growing healthcare sector, Pulse aims to address significant unmet clinical needs, deploying non-invasive and effective solutions to improve patient outcomes, particularly for conditions such as atrial fibrillation and benign thyroid disease.
Bull says
- ↑Q4 2025 revenue $264K, up from $86K in Q3 2025, showing early NSPFA traction.
- ↑NSPFA delivered 96% procedural success in atrial fibrillation ablations.
- ↑Cash reserves $106.3M as of Q2 2025 support clinical trials and R&D.
- ↑FDA granted breakthrough designation for NPulse systems, speeding approvals.
- ↑High momentum and positive analyst revisions suggest improving investor sentiment.
- ↑Elevated short interest could trigger a squeeze on favorable news.
Bear says
- ↓GAAP net loss widened to $19.2M in Q3 2025 vs $12.7M year-ago, raising sustainability concerns.
- ↓Q4 2025 cash burn of $14.8M risks depleting liquidity without revenue growth.
- ↓Cash down to $80.7M by Q4 2025 may require dilutive financing.
- ↓Regulatory approval delays and complex trials could push back commercialization.
- ↓Intense competition from Medtronic, Boston Scientific, Abbott Labs challenges market share.
- ↓Weak profitability and high leverage risk alongside investor skepticism limit upside.
Earnings Call · Q4 2024 · Mgmt. Guidance
Updated 07-03-2026neutral
Transcript signals
Bull points
- I'm extremely excited to join Pulse Biosciences and contribute to the development and commercialization of our nanosecond PFA devices to advance the treatment of several disease states.
- It is clear the team and the technology are world-class, and the opportunity set ahead is quite unique.
- In the fourth quarter, we strengthened our balance sheet considerably through the exercise of warrants related to the rights offering that was completed in July of 2024, raising an additional $47.9 million in net proceeds.
Bear points
- The increase in GAAP costs and expenses was primarily driven by an increase in non-cash stock-based compensation, which was $6.8 million in the fourth quarter of 2024, compared to $3.3 million in the prior year period, along with other compensation and administrative expenses to support the expanding organization and advancement of our NSPSA devices, along with severance and legal settlement expenses.
- Gap net loss in the fourth quarter of 2024 was $19.4 million compared to $11.9 million in the prior year period.
- Non-gap net loss in the fourth quarter of 2024 was $10.4 million compared to $8.3 million in the prior year period.
Read full transcript analysis ›